| Literature DB >> 33981689 |
María Belén Estevez1,2, María Laura Casaux3, Martín Fraga3, Ricardo Faccio4, Silvana Alborés1.
Abstract
Infectious diseases are one of the most important health problems worldwide, one of the main causes being the development of multi-resistant microorganisms. Likewise, the zoonotic potential of some pathogens and their ability to transfer resistance mechanisms, reduce the therapeutic options in both humans and animals. Salmonella enterica is an important pathogen that affects a wide range of animal species and humans, being Salmonella Typhimurium one of the most frequent serotypes affecting cattle, causing enteritis, diarrhea, and septicemia. The search for alternative therapeutic approaches has gained importance since the emergence of multidrug resistance to antibiotics and periodic outbreaks of salmonellosis. In this sense, the discovery of new drugs and the development of new strategies, such as the use of nanoparticles with antimicrobial activity, are very promising. The aim of this work was the extracellular production of biogenic silver nanoparticles using fungal extracts and the evaluation of their antimicrobial activity against resistant and multi-resistant Salmonella Typhimurium strains. We here demonstrated the potential of the biogenic nanoparticles as effective bacteriostatic and bactericidal agents for use in biomedical applications. In addition, Confocal Raman Microscopy and Atomic Force Microscopy were used to advance the understanding of the antimicrobial mechanism of biogenic nanoparticles against these pathogenic strains, the results of which suggested that the nanoparticles produced damage in several bacterial cell structures.Entities:
Keywords: Confocal Raman Microscopy; Salmonella Typhimurium; antimicrobial; biogenic nanoparticles; multi-resistance
Year: 2021 PMID: 33981689 PMCID: PMC8107374 DOI: 10.3389/fbioe.2021.644014
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
Antibiotic-resistance profile of Salmonella Typhimurium strains.
| 16-025M4 | Cefotaxime, streptomycin, tetracycline | – |
| 16-045M5 | Ciprofloxacin, enrofloxacin, streptomycin, tetracycline | – |
| 16-058M4 | Ampicillin, amoxicillin- clavulanic acid, trimethoprim-sulfamethoxazole streptomycin, tetracycline | – |
| 16-078M4 | Amoxicillin- clavulanic acid, streptomycin, tetracycline | Ampicillin |
| 17-032M21A | Enrofloxacin, gentamicin, streptomycin, tetracycline | Ciprofloxacin |
| 17081M3A | Ampicillin, nalidixic acid, ciprofloxacin, streptomycin, tetracycline | Clavulanic acid |
| 17-197M1 | Nalidixic acid, streptomycin, tetracycline | Gentamicin, nitrofurantoin, ciprofloxacin |
| 17-210M7B | Cefotaxime, streptomycin, gentamicin, tetracycline, azithromycin | Trimethoprim-sulfamethoxazole, ciprofloxacin |
| 19-027M2A | Ampicillin, trimethoprim-sulfamethoxazole, clavulanic acid, streptomycin, tetracycline, azithromycin | Amoxicillin- clavulanic acid, ciprofloxacin |
| 16-073M11 | Tetracycline | – |
FIGURE 1UV-Vis absorption spectrum after 24 h reaction.
FIGURE 2TEM image of the NPs.
FIGURE 3(A) DLS and (B) ζ-potential measurements of NPs in solution.
Minimum inhibitory and minimum bactericidal concentration of NPs and AgNO3 solution against Salmonella Typhimurium strains.
| 16-025M4 | 7.8 pM (0.3 ppm) | >15.6 pM | 39 μM | >830 μM |
| 16-045M5 | 7.8 pM (0.3 ppm) | 15.6 pM (0.6 ppm) | 39 μM | 830 μM |
| 16-058M4 | 15.6 pM (0.6 ppm) | 15.6 pM (0.6 ppm) | 39 μM | 830 μM |
| 16-078M4 | 7.8 pM (0.3 ppm) | >15.6 pM | 39 μM | 830 μM |
| 17-032M21A | 15.6 pM (0.6 ppm) | >15.6 pM | 78 μM | >1,250 μM |
| 17081M3A | 15.6 pM (0.6 ppm) | >15.6 pM | 78 μM | 1,250 μM |
| 17-197M1 | 15.6 pM (0.6 ppm) | 15.6 pM (0.6 ppm) | 39 μM | 1,250 μM |
| 17-210M7B | 15.6 pM (0.6 ppm) | >15.6 pM | 39μM | >830 μM |
| 19-027M2A | 15.6 pM (0.6 ppm) | >15.6 pM | 78 μM | 1,250 μM |
| 16-073M11 | 15.6 pM (0.6 ppm) | >15.6 pM | 78 μM | >1,250 μM |
Raman band assignment of bacterial cells (control).
| 557 | 556 | 545 | Carbohydrates |
| 709 | 745 | 713 | DNA, RNA |
| 757 | 761 | 796 | DNA, RNA |
| 800 | 810 | 807 | RNA |
| 935 | 970 | 934 | Lipids |
| 1,098 | 1,079 | 1,092 | Carbohydrates |
| 1,234 | 1,248 | 1,243 | RNA |
| 1,350 | 1,353 | 1,354 | Proteins |
| 1,444 | 1,448 | 1,462 | Lipids |
| 1,554 | 1,512 | 1,510 | Proteins |
| 1,594 | 1,575 | 1,579 | DNA, RNA |
FIGURE 4Comparison of average Raman spectra corresponding to Salmonella Typhimurium 17–197 M1 cells without treatment (pink) and treated with NPs (green). The intensity (in arbitrary units, AU) was normalized with respect to the signal intensity of the C-H band (2,900 cm–1 region). The decrease in the bands corresponding to RNA, carbohydrates and lipids after NPs treatment is shown.
FIGURE 5Confocal Raman images obtained by selecting the stretching C-H bands from the bacterial cells (pink) and the stretching Ag-N bands from the NPs (green). (a) Untreated cells. (b) NPs treated cells.
FIGURE 6Topographic and phase contrast AFM images of changes in the cell morphology after exposure of Salmonella Typhimurium to NPs (indicated by arrows). (A) Untreated cells (control). (B) NPs treated cells.